Computed tomography guided radio-frequency ablation of osteoid osteomas in atypical locations

Senne, Julie; Davis, Ryan M.; Yasin, Junaid; Brimmo, Olubusola; Evenski, Andrea; Bhat, Ambarish P.

doi:10.4103/ijri.ijri_259_19

Cited by 14 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 23 ] This may be in part due to the poor performance of RFA in the poor conducting environment of the lung parenchyma. [ 7 ] MWA is a newer technique that has been used as an alternative to RFA. The purported advantages of MWA over RFA include achieving higher temperatures, larger ablation zones, shorter ablation times, and reduced susceptibility to the heat-sink effect (inefficient ablation from the cooling effect of blood in adjacent vessels).…”

Section: Discussionmentioning

confidence: 99%

“…[ 3 ] Radiofrequency ablation (RFA) is a heat-based, safe, and effective ablation technique that has been used in the lung and other organs for local tumor control. [ 5 - 7 ] Due to some of its inherent limitations that include longer ablation times and susceptibility to “heat sink,” many operators now prefer microwave technology for heat-based ablations. In addition, microwave ablation (MWA) generates a larger heating radius within the poor conducting environment of the lung when compared to RFA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study

Nance

Khazi²,

Kaifi³

et al. 2021

JCIS

Self Cite

View full text Add to dashboard Cite

Objectives: The objective of the study was to retrospectively investigate the safety and efficacy of computerized tomography-guided microwave ablation (MWA) in the treatment of Stage I non-small cell lung cancers (NSCLCs). Material and Methods: This retrospective, single-center study evaluated 21 patients (10 males and 11 females; mean age 73.8 ± 8.2 years) with Stage I peripheral NSCLCs treated with MWA between 2010 and 2020. All patients were surveyed for metastatic disease. Clinical success was defined as absence of FDG avidity on follow-up imaging. Tumor growth within 5 mm of the original ablated territory was defined as local recurrence. Welch t-test and Fisher’s exact test were used for univariate analysis. Hazard ratio (HR) and odds ratio (OR) were determined using Cox regression and Firth logistic regression. Significance was P < 0.05. Data are expressed as mean ± standard deviation. Results: Ablated tumors had longest dimension 17.4 ± 5.4 mm and depth 19.7 ± 15.1 mm from the pleural surface. Median follow-up was 20 months (range, 0.6–56 months). Mean overall survival (OS) following lung cancer diagnosis or MWA was 26.2 ± 15.4 months (range, 5–56 months) and 23.7 ± 15.1 months (range, 3–55 months). OS at 1, 2, and 5 years was 67.6%, 61.8%, and 45.7%, respectively. Progression-free survival (PFS) was 19.1 ± 16.2 months (range, 1–55 months). PFS at 1, 2, and 5 years was 44.5%, 32.9%, and 32.9%, respectively. Technical success was 100%, while clinical success was observed in 95.2% (20/21) of patients. One patient had local residual disease following MWA and was treated with chemotherapy. Local control was 90% with recurrence in two patients following ablation. Six patients (28.6%) experienced post-ablation complications, with pneumothorax being the most common event (23.8% of patients). Female gender was associated with 90% reduction in risk of death (HR 0.1, P = 0.014). Tumor longest dimension was associated with a 10% increase in risk of death (P = 0.197). Several comorbidities were associated with increased hazard. Univariate analysis revealed pre-ablation forced vital capacity trended higher among survivors (84.7 ± 15.2% vs. 73 ± 21.6%, P = 0.093). Adjusted for age and sex, adenocarcinoma, and neuroendocrine histology trended toward improved OS (OR: 0.13, 0.13) and PFS (OR: 0.88, 0.37) compared to squamous cell carcinoma. Conclusion: MWA provides a safe and effective alternative to stereotactic brachytherapy resulting in promising OS and PFS in patients with Stage I peripheral NSCLC. Larger sample sizes are needed to further define the effects of underlying comorbidities and tumor biology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study

Nance

Khazi²,

Kaifi³

et al. 2021

JCIS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Treatment often involves neoadjuvant chemotherapy typically with ifosfamide and etoposide followed by a combination of surgical excision and radiation therapy. 4 5 21 22 23 24 25 Increased tumor burden and distant metastasis at presentation are associated with a poor overall survival. 4 The 5-year survival for patients with localized disease is around 60% and 40% for patients with metastatic disease.…”

Section: Discussionmentioning

confidence: 99%

Extraosseous Ewing’s Sarcoma: Pictorial Review of Imaging Findings, Differential Diagnosis, and Pathologic Correlation

Alexander

Hunter

Rubin

et al. 2021

Indian Journal of Radiology and Imaging

View full text Add to dashboard Cite

Extraosseous Ewing’s sarcoma (EES), first described in 1969, is a malignant mesenchymal tumor just like its intraosseous counterpart. Although Ewing’s sarcomas are common bone tumors in young children, EESs are rarer and more commonly found in older children/adults, often carrying a poorer prognosis. We discuss the multimodality imaging features of EES and the differential diagnosis of an aggressive appearing mass in proximity to skeletal structures, with pathologic correlates. This review highlights the need to recognize the variability of radiologic findings in EES such as the presence of hemorrhage, rich vascularity, and cystic or necrotic regions and its imaging similarity to other neoplasms that are closely related pathologically.

show abstract

“…Osteosarcoma is the most common primary malignant bone tumor, but uncommon in the axial skeleton with less than 3% found in the spine. 26 27 …”

Section: Malignant Tumorsmentioning

confidence: 99%

Demystifying Sacral Masses: A Pictorial Review

Senne

Nguyen

Staner

et al. 2021

Indian Journal of Radiology and Imaging

Self Cite

View full text Add to dashboard Cite

The sacrum is a triangular shaped bone made up of five fused vertebral bodies. It is composed of bone, cartilage, marrow elements as well as notochord remnants and is a common site for both benign and malignant (primary and secondary) tumors. Familiarity with the imaging features and clinical presentations of sacral bone tumors could be helpful in narrowing the differential diagnosis. Magnetic resonance imaging and computed tomography are the preferred imaging modalities for evaluating sacral masses. This pictorial review will highlight imaging features of common sacral tumors with pathologic correlation. Additionally, this article will review some critical principles and helpful tips to successfully biopsy these lesions.

show abstract

Computed tomography guided radio-frequency ablation of osteoid osteomas in atypical locations

Cited by 14 publications

References 28 publications

Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study

Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study

Extraosseous Ewing’s Sarcoma: Pictorial Review of Imaging Findings, Differential Diagnosis, and Pathologic Correlation

Demystifying Sacral Masses: A Pictorial Review

Contact Info

Product

Resources

About